BIOVENTURES, INC

Medtech · Private

Hybridization-triggered PCR (HT-PCR) technology and molecular biology reagents for point-of-care infectious disease diagnostics

bioventures.com →
Grants
$5.4M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$7K
1 award · Agriculture
#635 of 4531 in medtech
Patents
12
1 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Agriculture · Biomarker Kits And Dye For S&t-beltsville, Md/per M Nakhla.$6,719
Federal grantDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$287,251
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$878,071
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$2,557,898
Federal grantDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$886,669
Federal grantDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$394,585
Federal grantDepartment of Health and Human Services · Phase II · Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$398,573
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
632InCellDx, Inc.$10K$9.5M
633Insightra Medical, Inc.$9K$20M
634OSMIC ENTERPRISES, INC.$9K—
635BIOVENTURES, INC$7K—
636Biofrontera Inc.$6K$58M
637TRICOL BIOMEDICAL, INC$6K—
638Earlens Corp$5K$260M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 12
  • Method And Substances For Isolating Mirnasapplication
  • Method And Substances For Isolating Mirnasgranted
  • Devices And Methods For The Purification, Isolation, Desalting Or Buffer/solvent Exchange Of Substancesapplication
  • Method, Substances And Kits For Labeling Populations Of Rna And Other Subtances Containing Geminal Diolsapplication
  • Method For The Labeling And Detection Of Small Polynucleotidesapplication
  • Methods And Substances For Isolation And Detection Of Small Polynucleotidesapplication
  • Method And Substances For Isolating Mirnasapplication
  • Method And Device For The Collection And Isolation Of Nucleic Acidapplication
  • Method And Substances For Diagnosing Bipolar Disorderapplication
  • Chromosome 5 Genetic Variants Related To Dyslexiaapplication
  • Cytochrome P450 Genetic Variationsapplication
  • Method For Determining Polynucleotide Sequence Variationsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.